LEVOCARNITINE injection, solution
levocarnitine by
Drug Labeling and Warnings
levocarnitine by is a Prescription medication manufactured, distributed, or labeled by Devatis Inc., Deva Holding AS. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
-
DESCRIPTION
Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane.
The chemical name of levocarnitine is 3-carboxy-2(R)-hydroxy-N,N,N-trimethyl-1-propanaminium, inner salt. Levocarnitine is a white crystalline, hygroscopic powder. It is readily soluble in water, hot alcohol, and insoluble in acetone. The specific rotation of levocarnitine is between -29° and -32°. Its chemical structure is:
Empirical Formula: C 7H 15NO 3
Molecular Weight: 161.20
Levocarnitine Injection, USP is a sterile aqueous solution containing 1 g of levocarnitine per 5 mL vial. The pH is adjusted to 6.0 - 6.5 with hydrochloric acid or sodium hydroxide.
-
CLINICAL PHARMACOLOGY
Levocarnitine is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production.
Primary systemic carnitine deficiency is characterized by low concentrations of levocarnitine in plasma, RBC, and/or tissues. It has not been possible to determine which symptoms are due to carnitine deficiency and which are due to an underlying organic acidemia, as symptoms of both abnormalities may be expected to improve with Levocarnitine. The literature reports that carnitine can promote the excretion of excess organic or fatty acids in patients with defects in fatty acid metabolism and/or specific organic acidopathies that bioaccumulate acylCoA esters.1-6
Secondary carnitine deficiency can be a consequence of inborn errors of metabolism or iatrogenic factors such as hemodialysis. Levocarnitine may alleviate the metabolic abnormalities of patients with inborn errors that result in accumulation of toxic organic acids. Conditions for which this effect has been demonstrated are: glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency.7,8 Autointoxication occurs in these patients due to the accumulation of acylCoA compounds that disrupt intermediary metabolism. The subsequent hydrolysis of the acylCoA compound to its free acid results in acidosis which can be life-threatening. Levocarnitine clears the acylCoA compound by formation of acylcarnitine, which is quickly excreted. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. In premature infants and newborns, secondary deficiency is defined as plasma levocarnitine concentrations below age-related normal concentrations.
End Stage Renal Disease (ESRD) patients on maintenance hemodialysis may have low plasma carnitine concentrations and an increased ratio of acylcarnitine/carnitine because of reduced intake of meat and dairy products, reduced renal synthesis and dialytic losses. Certain clinical conditions common in hemodialysis patients such as malaise, muscle weakness, cardiomyopathy and cardiac arrhythmias may be related to abnormal carnitine metabolism.
Pharmacokinetic and clinical studies with Levocarnitine have shown that administration of levocarnitine to ESRD patients on hemodialysis results in increased plasma levocarnitine concentrations.
-
PHARMACOKINETICS
In a relative bioavailability study in 15 healthy adult male volunteers, Levocarnitine Tablets were found to be bio-equivalent to Levocarnitine Oral Solution. Following 4 days of dosing with 6 tablets of Levocarnitine 330 mg b.i.d. or 2 g of Levocarnitine oral solution b.i.d., the maximum plasma concentration (Cmax) was about 80 µmol/L and the time to maximum plasma concentration (Tmax) occurred at 3.3 hours.
The plasma concentration profiles of levocarnitine after a slow 3 minute intravenous bolus dose of 20 mg/kg of Levocarnitine were described by a two-compartment model. Following a single i.v. administration, approximately 76% of the levocarnitine dose was excreted in the urine during the 0-24h interval. Using plasma concentrations uncorrected for endogenous levocarnitine, the mean distribution half life was 0.585 hours and the mean apparent terminal elimination half life was 17.4 hours.
The absolute bioavailability of levocarnitine from the two oral formulations of Levocarnitine, calculated after correction for circulating endogenous plasma concentrations of levocarnitine, was 15.1 ± 5.3% for Levocarnitine Tablets and 15.9 ± 4.9% for Levocarnitine Oral Solution.
Total body clearance of levocarnitine (Dose/AUC including endogenous baseline concentrations) was a mean of 4.00 L/h.
Levocarnitine was not bound to plasma protein or albumin when tested at any concentration or with any species including the human.9
In a 9-week study, 12 ESRD patients undergoing hemodialysis for at least 6 months received Levocarnitine 20 mg/kg three times per week after dialysis. Prior to initiation of Levocarnitine therapy, mean plasma levocarnitine concentrations were approximately 20 µmol/L pre-dialysis and 6 µmol/L post-dialysis. The table summarizes the pharmacokinetic data (mean ± SD µmol/L) after the first dose of Levocarnitine and after 8 weeks of Levocarnitine therapy.
N=12
Baseline
Single dose
8 weeks
C max
-
1139 ± 240
1190 ± 270
Trough (pre-dialysis, pre-dose)
21.3 ± 7.7
68.4 ± 26.1
190 ± 55
After one week of Levocarnitine therapy (3 doses), all patients had trough concentrations between 54 and 180 µmol/L (normal 40-50 µmol/L) and concentrations remained relatively stable or increased over the course of the study.
In a similar study in ESRD patients also receiving 20 mg/kg Levocarnitine 3 times per week after hemodialysis, 12- and 24-week mean pre-dialysis (trough) levocarnitine concentrations were 189 (N=25) and 243 (N=23) µmol/L, respectively.
In a dose-ranging study in ESRD patients undergoing hemodialysis, patients received 10, 20, or
40 mg/kg Levocarnitine 3 times per week following dialysis (N~30 for each dose group). Mean ± SD trough levocarnitine concentrations (µmol/L) by dose after 12 and 24 weeks of therapy are summarized in the table.12 weeks
24 weeks
10 mg/kg
116 ± 69
148 ± 50
20 mg/kg
210 ± 58
240 ± 60
40 mg/kg
371 ± 111
456 ± 162
While the efficacy of Levocarnitine to increase carnitine concentrations in patients with ESRD undergoing dialysis has been demonstrated, the effects of supplemental carnitine on the signs and symptoms of carnitine deficiency and on clinical outcomes in this population have not been determined.
-
METABOLISM AND EXCRETION
In a pharmacokinetic study where five normal adult male volunteers received an oral dose of [3H-methyl]-L-carnitine following 15 days of a high carnitine diet and additional carnitine supplement, 58 to 65% of the administered radioactive dose was recovered in the urine and feces in 5 to 11 days. Maximum concentration of [3H-methyl]-L-carnitine in serum occurred from 2.0 to 4.5 hr after drug administration. Major metabolites found were trimethylamine N-oxide, primarily in urine (8% to 49% of the administered dose) and [3H]-γ-butyrobetaine, primarily in feces (0.44% to 45% of the administered dose). Urinary excretion of levocarnitine was about 4 to 8% of the dose. Fecal excretion of total carnitine was less than 1% of the administered dose.10
After attainment of steady state following 4 days of oral administration of Levocarnitine Tablets (1980 mg q12h) or Oral Solution (2000 mg q12h) to 15 healthy male volunteers, the mean urinary excretion of levocarnitine during a single dosing interval (12h) was about 9% of the orally administered dose (uncorrected for endogenous urinary excretion).
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
-
WARNINGS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following Levocarnitine administration, mostly in patients with end stage renal disease who are undergoing dialysis. Some reactions occurred within minutes after intravenous administration of Levocarnitine.
If a severe hypersensitivity reaction occurs, discontinue Levocarnitine treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering Levocarnitine to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.
-
PRECAUTIONS
General
The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine.
Drug Interactions
Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Mutagenicity tests performed in Salmonella typhimurium, Saccharomyces cerevisiae, and Schizosaccharomyces pombe indicate that levocarnitine is not mutagenic. No long-term animal studies have been performed to evaluate the carcinogenic potential of levocarnitine.
Pregnancy
Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on the basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus due to Levocarnitine. There are, however, no adequate and well controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers
Levocarnitine supplementation in nursing mothers has not been specifically studied.
Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment.
-
ADVERSE REACTIONS
Clinical Trials Experience
Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis. An incidence for these reactions is difficult to estimate due to the confounding effects of the underlying pathology.
The table below lists the adverse events that have been reported in two double-blind, placebo- controlled trials in patients on chronic hemodialysis. Events occurring at ≥5% are reported without regard to causality.
Adverse Events with a Frequency ≥5% Regardless of Causality by Body System Placebo (n=63)
Levocarnitine 10 mg (n=34)
Levocarnitine 20 mg (n=62)
Levocarnitine 40 mg (n=34)
Levocarnitine 10, 20 & 40 mg (n=130)
Body as Whole
Abdominal pain
17
21
5
6
9
Accidental injury
10
12
8
12
10
Allergic reaction
5
6
2
Asthenia
8
9
8
12
9
Back pain
10
9
8
6
8
Chest pain
14
6
15
12
12
Fever
5
6
5
12
7
Flu syndrome
40
15
27
29
25
Headache
16
12
37
3
22
Infection
17
15
10
24
15
Injection site reaction
59
38
27
38
33
Pain
49
21
32
35
30
Cardiovascular
Arrhythmia
5
3
3
2
Atrial fibrillation
2
6
2
Cardiovascular disorder
6
3
5
6
5
Electrocardiogram abnormal
3
6
2
Hemorrhage
6
9
2
3
4
Hypertension
14
18
21
21
20
Hypotension
19
15
19
3
14
Palpitations
3
8
5
Tachycardia
5
6
5
9
6
Vascular disorder
2
2
6
2
Digestive
Anorexia
3
3
5
6
5
Constipation
6
3
3
3
3
Diarrhea
19
9
10
35
16
Dyspepsia
10
9
6
5
Gastrointestinal disorder
2
3
6
2
Melena
3
6
2
Nausea
10
9
5
12
8
Stomach atony
5
Vomiting
16
9
16
21
15
Endocrine System
Parathyroid disorder
2
6
2
6
4
Hemic/Lymphatic
Anemia
3
3
5
12
6
Metabolic/Nutritional
Hypercalcemia
3
15
8
6
9
Hyperkalemia
6
6
6
6
6
Hypervolemia
17
3
3
12
5
Peripheral edema
3
6
5
3
5
Weight decrease
3
3
8
3
5
Weight increase
2
3
6
2
Musculo-Skeletal
Leg cramps
13
8
4
Myalgia
6
Nervous
Anxiety
5
2
1
Depression
3
6
5
6
5
Dizziness
11
18
10
15
13
Drug dependence
2
6
2
Hypertonia
5
3
1
Insomnia
6
3
6
4
Paresthesia
3
3
3
12
5
Vertigo
6
2
Respiratory
Bronchitis
5
3
3
Cough increase
16
10
18
9
Dyspnea
19
3
11
3
7
Pharyngitis
33
24
27
15
23
Respiratory disorder
5
Rhinitis
10
6
11
6
9
Sinusitis
5
2
3
2
Skin And Appendages
Pruritus
13
8
3
5
Rash
3
5
3
3
Special Senses
Amblyopia
2
6
3
Eye disorder
3
6
3
3
Taste perversion
2
9
3
Urogenital
Urinary tract infect
6
3
3
2
Kidney failure
5
6
6
6
6
Postmarketing Experience
The following adverse reactions have been reported:
Neurologic Reactions: Seizures have been reported to occur in patients, with or without pre- existing seizure activity, receiving either oral or intravenous levocarnitine. In patients with pre- existing seizure activity, an increase in seizure frequency and/or severity has been reported.
Hypersensitivity reactions: Anaphylaxis, laryngeal edema and bronchospasm (see WARNINGS).
- OVERDOSAGE
-
DOSAGE AND ADMINISTRATION
Levocarnitine Injection, USP is administered intravenously.
Metabolic Disorders
The recommended dose is 50 mg/kg given as a slow 2-3 minute bolus injection or by infusion. Often a loading dose is given in patients with severe metabolic crisis, followed by an equivalent dose over the following 24 hours. It should be administered q3h or q4h, and never less than q6h either by infusion or by intravenous injection. All subsequent daily doses are recommended to be in the range of 50 mg/kg or as therapy may require. The highest dose administered has been 300 mg/kg.
It is recommended that a plasma carnitine concentration be obtained prior to beginning this parenteral therapy. Weekly and monthly monitoring is recommended as well. This monitoring should include blood chemistries, vital signs, plasma carnitine concentrations (the plasma free carnitine concentration should be between 35 and 60 µmol/L) and overall clinical condition.
ESRD Patients on Hemodialysis
The recommended starting dose is 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session. Initiation of therapy may be prompted by trough (pre-dialysis) plasma levocarnitine concentrations that are below normal (40-50 µmol/L). Dose adjustments should be guided by trough (pre-dialysis) levocarnitine concentrations, and downward dose adjustments (e.g. to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- COMPATIBILITY AND STABILITY
-
HOW SUPPLIED
Levocarnitine Injection, USP is available in 1 g per 5 mL single dose vials packaged 5 vials per carton (NDC: 73043-034-05). Levocarnitine Injection, USP 5 mL vial is distributed by Devatis Inc.
Store vials at controlled room temperature (25°C). See USP. Discard unused portion of an opened vial, as the formulation does not contain a preservative.
Rx only.
-
REFERENCES
- Bohmer, T., Rydning, A. and Solberg, H.E. 1974. Carnitine levels in human serum in health and disease. Clin. Chim. Acta 57:55-61.
- Brooks, H., Goldberg, L., Holland, R. et al. 1977. Carnitine-induced effects on cardiac and peripheral hemodynamics. J. Clin. Pharmacol. 17:561-568.
- Christiansen, R., Bremer, J. 1976. Active transport of butyrobetaine and carnitine into
isolated liver cells. Biochim. Biophys. Acta 448:562-577. - Lindstedt, S. and Lindstedt, G. 1961. Distribution and excretion of carnitine in the rat. Acta Chem. Scand. 15:701-702.
- Rebouche, C.J. and Engel, A.G. 1983. Carnitine metabolism and deficiency syndromes. Mayo Clin. Proc. 58:533-540.
- Rebouche, C.J. and Paulson, D.J. 1986. Carnitine metabolism and function in humans. Ann. Rev. Nutr. 6:41-66.
- Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. 1989. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill.
- Schaub, J., Van Hoof, F. and Vis, H.L. 1991. Inborn Errors of Metabolism. New York: Raven Press.
- Marzo, A., Arrigoni Martelli, E., Mancinelli, A., Cardace, G., Corbelletta, C., Bassani, E. and Solbiati, M. 1991. Protein binding of L-carnitine family components. Eur. J. Drug Met. Pharmacokin., Special Issue III: 364-368.
- Rebouche, C.J. 1991. Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism 40:1305-1310.
Made in Turkey
Distributed by:
Devatis, Inc.
San Clemente, CA 92672Rev. 06/2025 - PRINCIPAL DISPLAY PANEL - CARTON LABEL
-
INGREDIENTS AND APPEARANCE
LEVOCARNITINE
levocarnitine injection, solutionProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC: 73043-034 Route of Administration INTRAVENOUS Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOCARNITINE (UNII: 0G389FZZ9M) (LEVOCARNITINE - UNII:0G389FZZ9M) LEVOCARNITINE 1 g in 5 mL Inactive Ingredients Ingredient Name Strength HYDROCHLORIC ACID (UNII: QTT17582CB) SODIUM HYDROXIDE (UNII: 55X04QC32I) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 73043-034-05 5 in 1 CARTON 11/01/2025 1 5 mL in 1 VIAL; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA217430 11/01/2025 Labeler - Devatis Inc. (116839699) Registrant - Deva Holding AS (116839699) Establishment Name Address ID/FEI Business Operations Deva Holding AS 502664398 manufacture(73043-034)
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.